UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 118

Sortiert nach

Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer

Annals of oncology, 2006-08, Vol.17 (8), p.1263-1268

2006

Volltextzugriff (PDF)

Development of a new G-CSF product based on biosimilarity assessment

Annals of oncology, 2010-07, Vol.21 (7), p.1419-1429

2010

Volltextzugriff (PDF)

A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2010-06, Vol.68 (3), p.420-426

2010

Volltextzugriff (PDF)

5050 POSTER Lapatinib (L) in Combination With Paclitaxel (P) is an Effective and Tolerable Treatment in HER2-overexpressing Metastatic Breast Cancer (MBC) Patients

European journal of cancer (1990), 2011, Vol.47, p.S345-S345

2011

Volltextzugriff (PDF)

Expression of Matrix Metalloproteinases 1, 2, 9 and Their Tissue Inhibitor-1 in Cartilage-Forming Osteal Tumors

Bulletin of experimental biology and medicine, 2010-09, Vol.149 (3), p.341-346

2010

Volltextzugriff (PDF)

Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study

Journal of clinical oncology, 2005-09, Vol.23 (25), p.5960-5972

2005

Volltextzugriff (PDF)

Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC)

JOURNAL OF CLINICAL ONCOLOGY, 2010, Vol.28 (18_suppl), p.LBA1010-LBA1010

2010

Volltextzugriff (PDF)

Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer

European journal of cancer (1990), 2013-12, Vol.49 (18), p.3831-3838

2013

Volltextzugriff (PDF)

First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study

Journal of clinical oncology, 2012-03, Vol.30 (9), p.921-929

2012

Volltextzugriff (PDF)

Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer

Journal of clinical oncology, 2009-02, Vol.27 (4), p.526-534

2009

Volltextzugriff (PDF)

Extralesional resection for tumours of the pelvic bones

International orthopaedics, 1997, Vol.21 (1), p.41-45

Makhson, A

1997

Volltextzugriff (PDF)

Soft tissue chondroma

Arkhiv patologii, 2009-03, Vol.71 (2), p.20

2009

Volltextzugriff (PDF)

3004 ORAL Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastastic colorectal cancer (mCRC): a large-scale phase II study, OPUS

European journal of cancer supplements, 2007-09, Vol.5 (4), p.236-236

2007

Volltextzugriff (PDF)

Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC)

European journal of cancer supplements, 2008, Vol.6 (7), p.172-172

2008

Volltextzugriff (PDF)

Abstract P4-12-08: Final efficacy results from a single-arm multicenter phase II study evaluating first-line trastuzumab, bevacizumab, and capecitabine (HAX) therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P4-P4-12-08

2013

Volltextzugriff (PDF)

Abstract P4-22-13: Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-1

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-22-13

2017

Volltextzugriff (PDF)

8064 Influence of an independent review on PFS and response assessments in a phase III clinical trial in relapsed ovarian cancer

European journal of cancer supplements, 2009, Vol.7 (2), p.468-468

2009

Volltextzugriff (PDF)

2106 POSTER Randomized clinical comparison of weekly or every-3-week 130-nanometer albumin-bound paclitaxel vs. every-3-week docetaxel as first-line therapy in patients with metastatic breast cancer

European journal of cancer supplements, 2007, Vol.5 (4), p.215-215

2007

Volltextzugriff (PDF)

Chondroblastoma

Arkhiv patologii, 2007-05, Vol.69 (3), p.53

2007

Volltextzugriff (PDF)

Osteocartilaginous exostoses (osteochondromas)

Arkhiv patologii, 2008-01, Vol.70 (1), p.58

2008

Volltextzugriff (PDF)

6563 POSTER High-dose 130-nanometer albumin-bound paclitaxel in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer

European journal of cancer supplements, 2007, Vol.5 (4), p.376-377

2007

Volltextzugriff (PDF)

Phase I, dose-finding study of monotherapy with AZD8931, an inhibitor of ErbB1, 2, and 3 signaling, in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3097-3097

2011

Volltextzugriff (PDF)

Phase III study of single-dose casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.9019-9019

2011

Volltextzugriff (PDF)

Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial

Journal of clinical oncology, 2011-09, Vol.29 (27_suppl), p.275-275

2011

Volltextzugriff (PDF)

First results of a phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment of HER2+ LA/MBC

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.571-571

2011

Volltextzugriff (PDF)

1 – 25 von 118

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(109)
Mit Volltextzugriff
(62)

Publikationsform

Artikel
(117)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(77)
Adult
(48)
Male
(46)
Female
(45)
Middle Aged
(41)
Aged
(27)
Life Sciences & Biomedicine
(24)
Science & Technology
(24)
Oncology
(19)
Aged, 80 And Over
(14)
Adolescent
(13)
Bone Neoplasms - Surgery
(13)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(11)
Hematology, Oncology And Palliative Medicine
(10)
Treatment Outcome
(10)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(8)
Breast Neoplasms - Drug Therapy
(8)
Bone Transplantation
(7)
Breast Neoplasms - Pathology
(7)
Osteomyelitis - Etiology
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer

Development of a new G-CSF product based on biosimilarity assessment

A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer

5050 POSTER Lapatinib (L) in Combination With Paclitaxel (P) is an Effective and Tolerable Treatment in HER2-overexpressing Metastatic Breast Cancer (MBC) Patients

Expression of Matrix Metalloproteinases 1, 2, 9 and Their Tissue Inhibitor-1 in Cartilage-Forming Osteal Tumors

Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study

Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC)

Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer

First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study

Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer

Extralesional resection for tumours of the pelvic bones

Soft tissue chondroma

3004 ORAL Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastastic colorectal cancer (mCRC): a large-scale phase II study, OPUS

Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC)

Abstract P4-12-08: Final efficacy results from a single-arm multicenter phase II study evaluating first-line trastuzumab, bevacizumab, and capecitabine (HAX) therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)

Abstract P4-22-13: Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-1

8064 Influence of an independent review on PFS and response assessments in a phase III clinical trial in relapsed ovarian cancer

2106 POSTER Randomized clinical comparison of weekly or every-3-week 130-nanometer albumin-bound paclitaxel vs. every-3-week docetaxel as first-line therapy in patients with metastatic breast cancer

Chondroblastoma

Osteocartilaginous exostoses (osteochondromas)

6563 POSTER High-dose 130-nanometer albumin-bound paclitaxel in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer

Phase I, dose-finding study of monotherapy with AZD8931, an inhibitor of ErbB1, 2, and 3 signaling, in patients (pts) with advanced solid tumors

Phase III study of single-dose casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting

Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial

First results of a phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment of HER2+ LA/MBC

Suchergebnisse filtern